Aktie A3D386 ORAGENICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Oragenics, Inc.

Aktien

A3D386

US6840235005

OGEN

Markt geschlossen - Nyse
Andere Börsenplätze
 22:00:00 26.06.2024 		% 5 Tage % 1. Jan.
1.01 USD +1.00% Intraday Chart für Oragenics, Inc. -33.99% -82.05%
25.06. Top Absteiger am Mittag MT
22.05. Oragenics, Inc. ernennt William ?Frank? Peacock MD zum Chief Clinical Officer CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Oragenics, Inc. Announces Closing of Public Offering
Top Midday Decliners
Oragenics, Inc. Announces Pricing of Public Offering
Oragenics, Inc. Announces Proposed Public Offering
Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance
Certain Series F Non-Voting, Convertible Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.
Certain Series B Non-Voting, Convertible Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.
Certain Series A Non-Voting, Convertible Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.
Certain Warrants of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.
Certain Options of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.
Certain Common Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.
Certain Series F Non-Voting, Convertible Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.
Certain Series B Non-Voting, Convertible Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.
Certain Series A Non-Voting, Convertible Preferred Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.
Certain Warrants of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.
Certain Options of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.
Certain Common Stock of Oragenics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.
Oragenics : Shareholder Meeting - Form 8-K
Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer
Oragenics, Inc. Appoints William ?Frank? Peacock MD as Chief Clinical Officer
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3D386 Aktie
  4. Nachrichten Oragenics, Inc.
  5. Andere Sprachen